Savara (NASDAQ:SVRA) Sees Large Volume Increase – Here’s What Happened

Savara Inc. (NASDAQ:SVRA) shares saw an uptick in trading volume on Wednesday. 4,789,849 shares changed hands during mid-day trading, an increase of 170% from the average daily volume of 1,774,836 shares. The stock last traded at $5.1050 and had previously closed at $4.92.

Analysts Set New Price Targets

SVRA has been the topic of several recent analyst reports. HC Wainwright started coverage on shares of Savara in a research note on Thursday. They set a “buy” rating and a $10.00 price objective on the stock. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. Citigroup reissued a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. began coverage on shares of Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.29.

Savara Stock Down 2.5%

The company has a debt-to-equity ratio of 0.28, a quick ratio of 10.13 and a current ratio of 8.55. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.53 and a beta of 0.32. The firm’s fifty day simple moving average is $4.95 and its 200 day simple moving average is $5.34.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.01. On average, sell-side analysts forecast that Savara Inc. will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Savara

Several institutional investors have recently added to or reduced their stakes in the stock. Profund Advisors LLC increased its holdings in Savara by 7.3% during the 3rd quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock worth $257,000 after purchasing an additional 3,370 shares in the last quarter. Sterling Capital Management LLC raised its position in Savara by 842.8% in the 3rd quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock valued at $26,000 after buying an additional 4,526 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Savara by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company’s stock valued at $190,000 after acquiring an additional 4,874 shares in the last quarter. Arizona State Retirement System lifted its stake in Savara by 34.0% in the 2nd quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock valued at $157,000 after acquiring an additional 6,456 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in shares of Savara in the first quarter valued at approximately $57,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.